BRIEF—ICER to review erenumab and revist plaque psoriasis therapies

The Institute for Clinical and Economic Review (ICER), the highly-referenced Boston, USA-based research institute, has announced it plans to conduct a formal review of erenumab.

The review will assess the comparative clinical effectiveness and value of erenumab for the prevention of migraine headaches.

The FDA’s decision on the therapy, under co-development by Novartis (NOVN: VX) and Amgen (Nasdaq: AMGN) is expected in May of 2018.

ICER also says it willl conduct an update to its 2016 report on therapies for plaque psoriasis, incorporating new evidence related to older therapies as well as the more recently-approved Tremfya (guselkumab), from Janssen.

That report will also look at the Sun Pharmaceutical’s (BSE: 524715) candidate tildrakizumab, which is currently under review by the US FDA with an expected decision in March of 2018.

ICER is financed by a mixture of charitable donations and industry sources. Funding from foundations, which makes up about 80% of the total, comes from the Laura and John Arnold Foundation (LJAF), the Blue Shield of California Foundation and others.